Krystal Biotech Quarterly Cash Flow Statement
NASDAQ: KRYSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Krystal Biotech free cash flow
In the quarter ended Jun 30, 2026, Krystal Biotech generated $74.8 million of operating cash flow and spent $3.6 million on capital expenditures. That left free cash flow of $71.2 million, a free-cash-flow margin of 59.7% of revenue. Free cash flow was up 40.1% from the prior year's $50.8 million.
Summary generated from market data by MetaCap's automated system. Methodology
Krystal Biotech cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 54.77M | 55.93M | 51.40M | 79.36M | 38.33M | 35.73M | 45.48M | 27.18M | 15.57M | 932.00K | 8.69M | 80.75M |
| Net Income growth (YoY) | +42.87% | +56.53% | +13.02% | +192.00% | +146.23% | +3734.01% | +423.23% | -66.34% | — | — | — | — |
| Depreciation & Amortization | 1.40M | 1.52M | 1.56M | 1.40M | 1.30M | 1.41M | 1.36M | 1.30M | 1.80M | 1.43M | 1.52M | 826.00K |
| Stock-Based Compensation | 14.16M | 13.61M | 13.76M | 13.15M | 14.12M | 13.48M | 13.36M | 13.32M | 13.16M | 9.30M | 9.85M | 8.31M |
| Change in Working Capital | -10.07M | -862.00K | 3.29M | -28.96M | -1.75M | -2.44M | -19.87M | 2.88M | -57.75M | -6.15M | -34.59M | -12.57M |
| Operating Cash Flow | 74.79M | 80.38M | 77.51M | 39.66M | 52.73M | 30.97M | 52.84M | 58.86M | -4.17M | 15.89M | -7.23M | -21.23M |
| Capital Expenditures | -3.56M | -7.15M | -2.14M | -1.70M | -1.90M | -6.20M | -801.00K | -1.05M | -1.13M | -1.26M | -1.85M | -1.78M |
| Investing Cash Flow | -161.58M | -63.58M | 11.16M | -4.29M | -10.53M | -54.77M | -83.78M | -34.33M | -19.35M | -25.98M | -10.16M | 105.19M |
| Financing Cash Flow | 15.05M | -10.46M | 15.67M | 3.71M | 1.80M | -12.47M | 2.43M | 3.37M | 10.64M | 10.58M | 2.62M | 13.39M |
| Net Change in Cash | -73.57M | 5.01M | 103.70M | 38.77M | 45.06M | -36.09M | -29.10M | 28.18M | -13.22M | 678.00K | -14.91M | 97.37M |
| Free Cash Flow | 71.22M | 73.23M | 75.37M | 37.95M | 50.83M | 24.77M | 52.04M | 57.81M | -5.30M | 14.63M | -9.08M | -23.01M |
This table shows 12 quarterly periods of Krystal Biotech's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow KRYS's reporting calendar. What is a cash flow statement?